SEARCH

SEARCH BY CITATION

References

  • 1
    Zhou P,Comenzo RL,Olshen AB, et al. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 2008; 111: 34033406. Epub 2008 Jan 23.
  • 2
    Bhat A,Selmi C,Naguwa SM, et al. Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol 2010; 38(2–3): 97106.
  • 3
    Picken MM. Amyloidosis: Where are we now and where are we heading? Arch Pathol Lab Med 2010; 134: 545551.
  • 4
    Chee CE,Lacy MQ,Dogan A, et al. Pitfalls in the diagnosis of primary amyloidosis. Clin Lymphoma Myeloma Leuk 2010; 10: 177180.
  • 5
    Mabru M,Dacher JN,Bauer F. Left ventricular hypertrophy: Cardiac magnetic resonance may help differentiate amyloidosis from hypertrophic cardiomyopathy. Arch Cardiovasc Dis 2010; 103: 5556. Epub 2009 Jun 2.
  • 6
    Perfetto F,Moggi-Pignone A,Livi R, et al. Systemic amyloidosis: A challenge for the rheumatologist. Nat Rev Rheumatol 2010; 6: 417429. Epub 2010 Jun 8.
  • 7
    Stratta P,Gravellone L,Cena T, et al. Renal outcome and monoclonal immunoglobulin deposition disease in 289 old patients with blood cell dyscrasias: A single center experience. Crit Rev Oncol Hematol, in press. [Epub 2010 May 28]
  • 8
    England JD,Gronseth GS,Franklin G, et al; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Practice parameter: the evaluation of distal symmetric polyneuropathy: The role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. PMR 2009; 1: 1422.
  • 9
    Sedaghat D,Zakir RM,Choe J, et al. Cardiac amyloidosis in a patient with multiple myeloma: A case report and review of literature. J Clin Ultrasound 2009; 37: 179184.
  • 10
    Tsang W,Lang RM. Echocardiographic evaluation of cardiac amyloid. Curr Cardiol Rep 2010; 12: 272276.
  • 11
    Cheng AS,Banning AP,Mitchell AR, et al. Cardiac changes in systemic amyloidosis: Visualisation by magnetic resonance imaging. Int J Cardiol 2006; 113: E21E23. Epub 2006 Oct 17.
  • 12
    Katzmann JA. Screening panels for monoclonal gammopathies: Time to change. Clin Biochem Rev 2009; 30: 105111.
  • 13
    Shaheen SP,Levinson SS. Serum free light chain analysis may miss monoclonal light chains that urine immunofixation electrophoreses would detect. Clin Chim Acta 2009; 406(1–2): 162166. Epub 2009 May 4.
  • 14
    Dispenzieri A,Kyle R,Merlini G, et al.; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009; 23: 215224. Epub 2008 Nov 20.
  • 15
    Kyle RA,Therneau TM,Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006; 354: 13621369.
  • 16
    Kyle RA,Gertz MA,Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 2133.
  • 17
    Gertz MA,Lacy MQ,Dispenzieri A, et al. Autologous stem cell transplantation for immunoglobulin light chain amyloidosis: A status report. Leukemia Lymphoma, in press. [Epub 2010 Oct 20]
  • 18
    Palladini G,Russo P,Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55: 499504. Epub 2009 Jan 8.
  • 19
    von Hutten H,Mihatsch M,Lobeck H, et al. Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol 2009; 33: 11981205.
  • 20
    Kieninger B,Eriksson M,Kandolf R, et al. Amyloid in endomyocardial biopsies. Virchows Arch 2010; 456: 523532. Epub 2010 Apr 8.
  • 21
    Petruzziello F,Zeppa P,Catalano L, et al. Amyloid in bone marrow smears of patients affected by multiple myeloma. Ann Hematol 2010; 89: 469474. Epub 2009 Nov 6.
  • 22
    van Gameren II,Hazenberg BP,Bijzet J, et al. Amyloid load in fat tissue reflects disease severity and predicts survival in amyloidosis. Arthritis Care Res (Hoboken) 2010; 62: 296301.
  • 23
    Dahdah MJ,Kurban M,Kibbi AG,Ghosn S. Primary localized cutaneous amyloidosis: A sign of immune dysregulation? Int J Dermatol 2009; 48: 419421.
  • 24
    Gallivan GJ,Gallivan HK. Laryngeal amyloidosis causing hoarseness and airway obstruction. J Voice 2010; 24: 235239. Epub 2008 Dec 25.
  • 25
    Javed A,Canales BK,Maclennan GT. Bladder amyloidosis. J Urol 2010; 183: 23882389. Epub 2010 Apr 18.
  • 26
    Roden AC,Aubry MC,Zhang K, et al. Nodular senile pulmonary amyloidosis: A unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study. Hum Pathol 2010; 41: 10401045. Epub 2010 Apr 8.
  • 27
    Biewend ML,Menke DM,Calamia KT. The spectrum of localized amyloidosis: A case series of 20 patients and review of the literature. Amyloid 2006; 13: 135142.
  • 28
    Comenzo RL,Zhou P,Fleisher M, et al. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood 2006; 107: 34893491. Epub 2006 Jan 26.
  • 29
    Linke RP,Oos R,Wiegel NM,Nathrath WB. Classification of amyloidosis: Misdiagnosing by way of incomplete immunohistochemistry and how to prevent it. Acta Histochem 2006; 108: 197208. Epub 2006 Jun 21.
  • 30
    Gruys E,Ultee A,Upragarin N. Glycosaminoglycans are part of amyloid fibrils: Ultrastructural evidence in avian AA amyloid stained with cuprolinic blue and labeled with immunogold. Amyloid 2006; 13: 1319.
  • 31
    Vrana JA,Gamez JD,Madden BJ, et al. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 49574959. Epub 2009 Oct 1.
  • 32
    Desai HV,Aronow WS,Peterson SJ,Frishman WH. Cardiac amyloidosis: Approaches to diagnosis and management. Cardiol Rev 2010; 18: 111.
  • 33
    Koyama J,Falk RH. Prognostic significance of strain Doppler imaging in light-chain amyloidosis. JACC Cardiovasc Imaging 2010; 3: 333342.
  • 34
    Dispenzieri A,Gertz MA,Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis. J Clin Oncol 2004; 22: 37513757.
  • 35
    Dispenzieri A,Gertz MA,Kyle RA, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 18811887. Epub 2004 Mar 25.
  • 36
    Kumar S,Dispenzieri A,Gertz MA. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2008; 358: 91.
  • 37
    Gertz M,Lacy M,Dispenzieri A, et al. Troponin T level as an exclusion criterion for stem cell transplantation in light-chain amyloidosis. Leuk Lymphoma 2008; 49: 3641.
  • 38
    Dispenzieri A,Lacy MQ,Zeldenrust SR, et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465470. Epub 2006 Sep 28.
  • 39
    Yoshida T,Matsuda M,Katoh N, et al. Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis. Intern Med 2008; 47: 17831790. Epub 2008 Oct 15.
  • 40
    Kumar S,Dispenzieri A,Katzmann JA, et al. Serum immunoglobulin free light chain measurement in AL amyloidosis: Prognostic value and correlations with clinical features. Blood, in press. [Epub 2010 Aug 26]
  • 41
    Gertz MA,Zeldenrust SR. Treatment of immunoglobulin light chain amyloidosis. Curr Hematol Malig Rep 2009; 4: 9198.
  • 42
    Kumar S,Dispenzieri A,Lacy MQ, et al. Serum uric acid: Novel prognostic factor in primary systemic amyloidosis. Mayo Clin Proc 2008; 83: 297303.
  • 43
    Jones NF,Hilton PJ,Tighe JR,Hobbs JR. Treatment of “primary” renal amyloidosis with melphalan. Lancet 1972; 2: 616619.
  • 44
    Kyle RA,Bayrd ED. Amyloidosis: Review of 236 cases. Medicine (Baltimore) 1975; 54: 271299.
  • 45
    Comenzo RL,Vosburgh E,Simms RW, et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients. Blood 1996; 88: 28012806.
  • 46
    Dispenzieri A,Merlini G,Comenzo RL. Amyloidosis 2008 BMT Tandem Meetings (February 13–17, San Diego). Biol Blood Marrow Transplant 2008; 14( Suppl 1): 611.
  • 47
    Jaccard A,Moreau P,Leblond V, et al.; Myelome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 2007; 357: 10831093.
  • 48
    Mhaskar R,Kumar A,Behera M, et al. Role of high-dose chemotherapy and autologous hematopoietic cell transplantation in primary systemic amyloidosis: A systematic review. Biol Blood Marrow Transplant 2009; 15: 893902. Epub 2009 Apr 2.
  • 49
    Mehta J,Dispenzieri A,Gertz MA. High-dose chemotherapy with autotransplantation in AL amyloidosis: A flawed meta-analysis. Biol Blood Marrow Transplant 2010; 16: 138140. Epub 2009 Sep 15.
  • 50
    Sanchorawala V,Skinner M,Quillen K, et al. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood 2007; 110: 35613563. Epub 2007 Aug 2.
  • 51
    Gertz MA,Lacy MQ,Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: Outcomes before and after 2006. Bone Marrow Transplant, in press. [Epub 2010 Oct 11]
  • 52
    Gertz MA,Lacy MQ,Dispenzieri A, et al. Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: Importance of achieving a complete response. Haematologica 2007; 92: 14151418.
  • 53
    Gertz MA,Lacy MQ,Dispenzieri A, et al. Transplantation for amyloidosis. Curr Opin Oncol 2007; 19: 136141.
  • 54
    Skinner M,Anderson J,Simms R, et al. Treatment of 100 patients with primary amyloidosis: A randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 1996; 100: 290298.
  • 55
    Kyle RA,Gertz MA,Greipp PR, et al. A trial of three regimens for primary amyloidosis: Colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med 1997; 336: 12021207.
  • 56
    Sanchorawala V,Wright DG,Seldin DC, et al. Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 2002; 117: 886889.
  • 57
    Palladini G,Perfetti V,Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 29362938. Epub 2003 Dec 18.
  • 58
    Palladini G,Russo P,Nuvolone M, et al. Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis. Blood 2007; 110: 787788.
  • 59
    Lebovic D,Hoffman J,Levine BM, et al. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol 2008; 143: 369373. Epub 2008 Aug 4.
  • 60
    Dietrich S,Schonland SO,Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 2010; 116: 522528. Epub 2010 Apr 7.
  • 61
    Gertz MA. I don't know how to treat amyloidosis. Blood 2010; 116: 507508.
  • 62
    Blade J,Rosinol L. Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies. Clin Lymphoma 2003; 3: 247248.
  • 63
    Dispenzieri A,Lacy MQ,Rajkumar SV, et al. Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003; 10: 257261.
  • 64
    Palladini G,Russo P,Lavatelli F, et al. Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide. Ann Hematol 2009; 88: 347350. Epub 2008 Sep 9.
  • 65
    Wechalekar AD,Goodman HJ,Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457464. Epub 2006 Sep 21.
  • 66
    Sviggum HP,Davis MD,Rajkumar SV,Dispenzieri A. Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol 2006; 142: 12981302.
  • 67
    Sanchorawala V,Wright DG,Rosenzweig M, et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 2 trial. Blood 2007; 109: 492496. Epub 2006 Sep 7.
  • 68
    Moreau P,Jaccard A,Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly-diagnosed AL amyloidosis: A multicenter phase 1/2 dose escalation study. Blood, 2010; 116: 47774782.
  • 69
    Kumar S,Hayman SR,Buadi F, et al. A phase II trial of lenalidomide, cyclophosphamide and dexamethasone (RCD) in patients with light chain amyloidosis [abstract 3853]. Blood 2009; 114.
  • 70
    Gillmore J,Cocks K,Gibbs SDJ, et al. Cyclophosphamide, thalidomide and dexamethasone (CTD) versus melphalan plus dexamethasone (MD) for newly-diagnosed systemic AL amyloidosis: Results from the UK amyloidosis treatment trial [abstract 2869]. Blood 2009; 114.
  • 71
    Dispenzieri A,Gertz MA,Hayman SR, et al. A pilot study of pomalidomide and dexamethasone in previously treated light chain amyloidosis patients [abstract 3854]. Blood 2009; 114.
  • 72
    Wechalekar AD,Lachmann HJ,Offer M, et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93: 295298.
  • 73
    Sitia R,Palladini G,Merlini G. Bortezomib in the treatment of AL amyloidosis: Targeted therapy? Haematologica 2007; 92: 13021307.
  • 74
    Reece DE,Sanchorawala V,Hegenbart U, et al.; VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: Results of a phase 1 dose-escalation study. Blood 2009; 114: 14891497. Epub 2009 Jun 4.
  • 75
    Brunvand MW,Bitter M. Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: Normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant. Haematologica 2010; 95: 519521. Epub 2009 Nov 10.
  • 76
    Kastritis E,Wechalekar AD,Dimopoulos MA, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 2010; 28: 10311037. Epub 2010 Jan 19.
  • 77
    Lamm W,Willenbacher W,Lang A, et al. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol 2010, in press. [Epub 2010 Sep 7]